About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
  About Us
  Research & Development
  Branded Formulations
  Financial Results
  - Q1 FY18 Earnings Call Details
  - FY17 Results
  - Investor Presentation
  - Chairman's AGM 2016 Speech
  - Annual Reports
  Facilities Virtual Tour
  - Biocon Profile
  - CMD Profile
  - Video Gallery

 Annual Report 2017

Annual Report 2017

  Biocon Academy



Biocon Ltd., Asia's premier biopharmaceutical company, is committed to ensure a global right to healthcare by addressing the worldwide need for safe, effective and affordable biotherapeutics. We have harnessed the power of biotechnology through affordable innovation to enhance access to new and differentiated therapies for diseases that are chronic, where medical needs are largely unmet.

The Company is a pioneer in bringing the benefit of high quality, yet affordable, novel biologics and biosimilars to patients in India and other emerging markets. Today, we are India's largest and fully-integrated biopharmaceutical company that develops, manufactures and supplies advanced, life-saving biopharmaceuticals for diabetes, cancer and autoimmune conditions at price points that make them affordable and thus accessible.

As an innovation-led organization focused on providing affordable access, we have leveraged our inherent strengths in advanced science to develop, manufacture and deliver a rich portfolio of Small Molecules APIs & Formulations and Complex Biologics - both Novels and Biosimilars - including Monoclonal Antibodies (MAbs), rh-insulin and Insulin Analogs.

Our global scale capacities for manufacturing high quality, affordable biologics have positioned us as the world's fourth largest insulins producer, enabling us to address the growing needs of diabetes patients across the globe. As one of the leading oncology companies in India, we have brought safe, efficacious and affordable medicines for cancer to cater to the needs of patients, caregivers and medical practitioners in the country.


KMS views on ODAC’s recommendation of Trastuzumab approval by USFDA on CNBC TV 18


Kiran Mazumdar - Shaw's view on FDA Oncologic Drugs Advisory Committee Unanimously Recommendation of Proposed Biosimilar Trastuzumab by Mylan and Biocon’s
(Video Credit: CNBC TV 18)

Kiran Mazumdar - Shaw outlines details on ANSM (French Regulator) GMP Compliance Report on CNBC TV 18


Two Biologics Drug Substance plants received ANSM (French Regulator) GMP Compliance Report. Drug Product facility Corrective And Preventive Action (CAPA) plan in progress.
(Video Credit: CNBC TV 18)

Biocon: Engaged in Affordable
Innovation for Global Impact
Stock Update

  Latest Press Release  

Jul. 14, 2017 
 FDA Oncologic Drugs  Advisory Committee  Unanimously  Recommends  Approval of Mylan and  Biocon’s Proposed  Biosimilar Trastuzumab

Jul. 09, 2017 
 Biocon Company Statement  on ANSM Inspection  Report

Jun. 11, 2017 
 Mylan and Biocon Present  Clinical Data on Insulin  Glargine at the American  Diabetes Association's 77th  Scientific Sessions



Biocon Malaysia

  Media Coverage  

 July 2017:
 It's Biocon's day in the sun

 July 2017:
 US FDA Panel Nod for Biocon  Breast Cancer Drug  Biosimilar








Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2016, Biocon. All Rights Reserved